Background
Phase III RCT (CheckMate 141) of 361 patients with recurrent squamous-cell carcinoma of the head and neck progressing <6mo after platinum-based chemotherapy, randomized 2:1 to nivolumab or investigator's-choice single-agent therapy.
Interventions and follow up
Arm A: nivolumab 3 mg/kg q2wk
Arm B: investigator's choice of weekly chemotherapy – methotrexate 40-60 mg/m2 IV q1wk, docetaxel 30-40 mg/m2 q1wk, or cetuximab 250 mg/m2 q1wk (400 mg/m2 loading)
Primary endpoint: overall survival
Arm B: investigator's choice of weekly chemotherapy – methotrexate 40-60 mg/m2 IV q1wk, docetaxel 30-40 mg/m2 q1wk, or cetuximab 250 mg/m2 q1wk (400 mg/m2 loading)
Primary endpoint: overall survival
Results
mOS: 7.5mo vs 5.1mo (arm A vs B); HR 0.70, 97.73% CI 0.51-0.96; P=.01
1-yr OS: 36.0% vs 16.6%
mPFS: 2.0mo vs 2.3mo; HR 0.89, 95% CI 0.70-1.13; P=.32
6-mo PFS: 19.7% vs 9.9%
ORR: 13.3% vs 5.8%
mOS PD-L1 ≥1%: HR 0.55, 95% CI 0.36-0.83
mOS PD-L1 <1%: HR 0.89, 95% CI 0.54-1.45; P=.17
mOS p16+: 9.1mo vs 4.4mo; HR 0.56, 95% CI 0.32-0.99
mOS p16-: 7.5mo vs 5.8mo; HR 0.73, 95% CI 0.42-1.25; P=.55
1-yr OS: 36.0% vs 16.6%
mPFS: 2.0mo vs 2.3mo; HR 0.89, 95% CI 0.70-1.13; P=.32
6-mo PFS: 19.7% vs 9.9%
ORR: 13.3% vs 5.8%
mOS PD-L1 ≥1%: HR 0.55, 95% CI 0.36-0.83
mOS PD-L1 <1%: HR 0.89, 95% CI 0.54-1.45; P=.17
mOS p16+: 9.1mo vs 4.4mo; HR 0.56, 95% CI 0.32-0.99
mOS p16-: 7.5mo vs 5.8mo; HR 0.73, 95% CI 0.42-1.25; P=.55
Adverse events
Overall: grade 3-4 treatment-related AEs 13.1% with nivolumab vs 35.1% with chemotherapy
Selected events (arm A vs B): GI/diarrhea 6.8% vs 14.4%; dermatologic/pruritus 15.7% vs 12.6%; hypothyroidism 7.6% vs 0.9%; pneumonitis 2.1% in nivolumab arm
Selected events (arm A vs B): GI/diarrhea 6.8% vs 14.4%; dermatologic/pruritus 15.7% vs 12.6%; hypothyroidism 7.6% vs 0.9%; pneumonitis 2.1% in nivolumab arm
Conclusions
Nivolumab significantly improved overall survival versus standard single-agent therapy in platinum-refractory recurrent HNSCC, with benefit most pronounced in PD-L1 ≥1% and/or p16-positive disease, and a more favorable toxicity profile.
Key Limitations
Open-label; heterogeneous comparator arm; subgroup OS analyses by PD-L1/p16 were exploratory and not powered; modest absolute OS gain. No PFS benefit, reflecting delayed immunotherapy effect.
Clinical Context
CheckMate 141 led to FDA and EMA approval of nivolumab for platinum-refractory R/M HNSCC, establishing PD-1 blockade as standard second-line therapy. ESMO guidelines recommend anti-PD-1 therapy (nivolumab or pembrolizumab) for platinum-refractory recurrent/metastatic HNSCC.